Company / EPS (Diluted)
Charles River Laboratories EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.91
FY2025
5-year range
-$2.91 / $9.48
FY2021-FY2025
Trend
-130.7%
vs FY2024
Sector context
#144 of 159
Health Care
What the data says
Among 159 Health Care companies, Charles River Laboratories is in the bottom 9% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-2.91 in FY2025 to $9.48 in FY2024.
Based on SEC 10-K filings.
-2.91 in FY2025.
Declined from $7.60 to $-2.91 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 159This company -$2.91 Sector average $2.35
▼
-223.7% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 130.7% year-over-year.
- Ranks #144 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.91 | -130.7% |
| FY2024 | $9.48 | +24.7% |
| FY2023 | $7.60 | +5.6% |
| FY2022 | $7.20 | +42.0% |
| FY2021 | $5.07 | +9.7% |
| FY2020 | $4.62 | +81.9% |
| FY2019 | $2.54 | -21.4% |
| FY2018 | $3.23 | +3.2% |
| FY2017 | $3.13 | +17.7% |
| FY2016 | $2.66 | +25.5% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026